HC Wainwright Has Positive Forecast for TARA Q4 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Research analysts at HC Wainwright lifted their Q4 2025 earnings estimates for Protara Therapeutics in a research report issued on Monday, November 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.36). HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q1 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.34) EPS.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Monday, November 10th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.60.

Protara Therapeutics Stock Down 2.0%

Protara Therapeutics stock opened at $7.41 on Wednesday. The stock has a 50-day moving average price of $5.16 and a 200 day moving average price of $3.84. The company has a market capitalization of $285.93 million, a price-to-earnings ratio of -4.57 and a beta of 1.59. Protara Therapeutics has a 52 week low of $2.48 and a 52 week high of $10.48.

Institutional Investors Weigh In On Protara Therapeutics

A number of institutional investors have recently modified their holdings of TARA. Acorn Capital Advisors LLC increased its stake in shares of Protara Therapeutics by 36.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock valued at $5,309,000 after purchasing an additional 472,315 shares in the last quarter. Velan Capital Investment Management LP grew its holdings in Protara Therapeutics by 28.3% in the second quarter. Velan Capital Investment Management LP now owns 2,139,000 shares of the company’s stock valued at $6,481,000 after purchasing an additional 471,200 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Protara Therapeutics in the second quarter valued at approximately $1,212,000. Geode Capital Management LLC raised its stake in shares of Protara Therapeutics by 114.7% during the 2nd quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock worth $2,256,000 after buying an additional 397,822 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Protara Therapeutics during the 2nd quarter valued at approximately $1,098,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.